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Tools for Detection of Mycoplasma amphoriforme: a Primary
Respiratory Pathogen?
Clare L. Ling,a* Katarina Oravcova,b Thomas F. Beattie,b,c Dean D. Creer,d Paul Dilworth,e Naomi L. Fulton,f Alison Hardie,f
Michelle Munro,f Marcus Pond,g Kate Templeton,f David Webster,h Sarita Workman,h Timothy D. McHugh,a Stephen H. Gillespieb
Centre for Clinical Microbiology, Department of Infection, Royal Free Campus, University College London, London, United Kingdoma; School of Medicine, University of St.
Andrews, St. Andrews, United Kingdomb; Royal Hospital for Sick Children, Edinburgh, United Kingdomc; Respiratory Medicine, Barnet General Hospital, London, United
Kingdomd; University College London Medical School, London, United Kingdome; Department of Medical Microbiology, Royal Infirmary, Edinburgh, United Kingdomf;
Centre for Infection and Immunity, St. George’s University of London, London, United Kingdomg; Department of Immunology, Royal Free London NHS Foundation Trust,
London, United Kingdomh
Mycoplasma amphoriforme is a recently described organism isolated from the respiratory tracts of patients with immunodefi-
ciency and evidence of chronic infection. Novel assays for the molecular detection of the organism by real-time quantitative
PCRs (qPCRs) targeting the uracil DNA glycosylase gene (udg) or the 23S rRNA gene are described here. The analytical sensitivi-
ties are similar to the existing conventionalM. amphoriforme 16S rRNA gene PCR, with the advantage of being species specific,
rapid, and quantitative. By using these techniques, we demonstrate the presence of this organism in 17 (19.3%) primary anti-
body-deficient (PAD) patients, 4 (5%) adults with lower respiratory tract infection, 1 (2.6%) sputum sample from a patient at-
tending a chest clinic, and 23 (0.21%) samples submitted for viral diagnosis of respiratory infection, but not in normal adult con-
trol subjects. These data show the presence of this microorganism in respiratory patients and suggest thatM. amphoriformemay
infect both immunocompetent and immunocompromised people. Further studies to characterize this organism are required,
and this report provides the tools that may be used by other research groups to investigate its pathogenic potential.
Mycoplasma amphoriforme was first isolated in 1999 from apatient with primary antibody deficiency (PAD) with
chronic bronchitis. It has also been isolated subsequently from
both immunocompromised and immunocompetent patients
with respiratory tract infections (RTI) in London, Denmark,
France, and Tunisia (1–3). Based on 16S rRNA sequencing, M.
amphoriforme belongs to the same phylogenetic group as other
human pathogenic Mycoplasma species, the pneumoniae group
(1, 2). The closest species phylogenetically for which there is a
whole-genome sequence is Mycoplasma gallisepticum, a bird
pathogen. Phenotypic studies have demonstrated that M. am-
phoriforme has features in common with this group, including
gliding motility, a protruding polar tip resembling that of M. gal-
lisepticum, and a cytoskeletal structure at its polar tip with homol-
ogy to that of M. pneumoniae’s attachment organelle (1, 4).
To understand the role that this novel agent plays in human
health, better laboratory tools are required. M. amphoriforme is
fastidious, requiring specializedmedia for cultivation, and it takes
approximately 2 weeks for colonies to appear on agar. The colo-
nial morphology resembles granular droplets, making detection
difficult, as the droplets can blend into the sample matrix and be
overlooked. This paper reports the development and evaluation of
two real-time quantitative PCR (qPCR) assays: one assay targeting
M. amphoriforme’s uracil DNA glycosylase gene (udg) and one
assay targeting the variable region of the 23S rRNA gene that is
unique toM. amphoriforme. The new qPCR assays were compared
with a previously reported 16S rRNA gene assay (2) and used to
test a range of human samples from the United Kingdom.
MATERIALS AND METHODS
Patients, samples, and ethical approval. Clinical samples from two hos-
pitals were used in this study: from the Royal Free London NHS Founda-
tionTrust (RFL),Hampstead, and from theRoyal Infirmary of Edinburgh
(RIE). Approvals were obtained from the Ethics Committee of the RFL
Hampstead and from the Lothian Regional Ethics Committee (08/S11/
02/2) to retain information during the steps taken to retain anonymity for
epidemiological purposes.
From 19 October 2000 to 6 September 2005, sputum samples were
collected from PAD patients attending the dedicated Primary Immuno-
deficiency Clinic at the RFL. These patients attended the clinic for either a
routine appointment or in cases of clinical deterioration. A sputum sam-
ple was collected from any patient with a productive cough and sent for
microbiological investigation, including detection of Mycoplasma
amphoriforme. The age range of all the PAD patients tested was 18 to 79
years, with an average age of 44 years.
Sputum and/or throat swab samples were collected from adult pa-
tients attending the RFL Chest Clinic and from adult patients (18 years
old) with lower respiratory tract infection (LRTI) who were recruited
from two general practices withmultiethnic patient populations (in total)
of 15,000 and from social classes I to V, as described previously (5). All
LRTI patients were surgery attendees; no recruitment was undertaken
outside of clinic hours or on home visits. Acute LRTI was defined as a new
or worsening cough and at least one other lower respiratory tract symp-
tom for which there was no other explanation, present for 21 days or less
(6, 7). Patients were excluded if they had underlying chronic suppurative
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lung disease (defined as bronchiectasis, lung abscess, or empyema), tuber-
culosis, immunodeficiency, or previous study participation (in the previ-
ous 3 weeks). Age-, sex-, and season-matched controls were recruited
from general practice patients attending the clinic for nonrespiratory and
noninfective illnesses as well as other healthy volunteers with no history of
respiratory tract symptoms for the 2 months prior to recruitment; these
control subjects were recruited using the same exclusion criteria as previ-
ously described for patients (5).
Respiratory samples (coded for anonymity) submitted for viral diag-
nosis, including sputum, nasopharyngeal secretions, and throat swabs
collected at hospital and primary care settings in southeast Scotland from
adults and children referred to the RIE Specialist Virology Centre (SVC)
with suspected respiratory infection, were tested. The ages of the patients
ranged from 0 to 96 years, with a mean of 19.91 years. The stored data for
these samples include the age group, partial postal code, any recorded
symptoms or clinical information, referral source, month of sample col-
lection, and results of other virological testing of the sample.
Control organisms.The following control organismswere used to test
the specificity of the assays: M. amphoriforme NCTC 11740 and Myco-
plasma pneumoniae ATCC 5167 (Mycoplasma Experience Ltd., United
Kingdom); Mycoplasma testudinis NCTC 11701 and Mycoplasma alvi
ATCC 29626 (Leahurst, United Kingdom); Acholeplasma laidlawiiATCC
23206, Mycoplasma buccale ATCC 23636, Mycoplasma faucium ATCC
25293, Mycoplasma fermentans ATCC 19989, Mycoplasma genitalium
ATCC 33530, Mycoplasma hominis ATCC 23114, Mycoplasma orale
ATCC 23714, Mycoplasma pirum ATCC 25960, Mycoplasma pneumoniae
NCTC 10119, and Mycoplasma salivarium ATCC 23064 (Public Health
England, United Kingdom); Streptococcus pneumoniae ATCC 49619,
Klebsiella sp. ATCC 700603, Staphylococcus aureus NCTC 6571, Esche-
richia coli NCTC 10418, Pseudomonas aeruginosa NCTC 10662, Haemo-
philus influenzae NCTC 11931, Legionella pneumophila NCTC 11192,
Neisseria gonorrhoeae NCTC 12700, and Mycobacterium tuberculosis
H37Rv ATCC 27294 (Department of Microbiology, Royal Free NHS
Trust, United Kingdom); coagulase-negative Staphylococcus, methicillin-
resistant Staphylococcus aureus, Moraxella catarrhalis, Neisseria meningi-
tidis, Bordetella pertussis, Streptococcus pyogenes, Acinetobacter spp.,
Corynebacterium spp., Proteus mirabilis, andCandida albicans clinical iso-
lates (Department of Microbiology, Royal Free London NHS Foundation
Trust); Pneumocystis jirovecii clinical isolate (Microbiology Department,
Raigmore Hospital, United Kingdom); Pneumocystis jirovecii, Candida
spp., and Aspergillus fumigatus (RIE SVC, Edinburgh, United Kingdom);
Chlamydia pneumoniae SA2f (Clinical Microbiology Department, Uni-
versity College London Hospitals NHS Foundation Trust, United King-
dom). The following viruses were also included for evaluation of assay
specificity (all from RIE SVC, Edinburgh, United Kingdom): influenza A
virus, influenza B virus, respiratory syncytial virus (RSV), parainfluenza
virus (PIV1 to -4), humanmetapneumovirus, human rhinovirus, human
coronavirus (hCoV; 229E, OC43, NL63, HKU1, and hEV), measles virus,
mumps virus, and human bocavirus (hBoV, types 1 to 4).
Culture methods. Respiratory samples from patients with PAD were
inoculated immediately on Mycoplasma Experience agar (Mycoplasma
Experience Ltd., Reigate, United Kingdom) and incubated at 36°C in gas
jars containing CO2 gas packs (Oxoid, Basingstoke, United Kingdom). A
small number of cultures that had been stored at 4°C for less than 4 days
were included, as this has been shown previously not to affect the viability
of M. amphoriforme (data not shown). Potential M. amphoriforme colo-
nies were detected microscopically at40 magnification, and their iden-
tities were confirmed by using M. amphoriforme 16S rRNA PCR and se-
quencing. Primary cultures contaminated with other microorganisms
were recultured using Sputasol-treated samples that had been stored at
20°C. Mycoplasma culture was also performed on 16S rRNA PCR-pos-
itive samples from the RFL Chest Clinic, but it was not performed on
samples from patients with LRTI in the general practice clinic, as these
samples had undergone heat killing prior to storage at70°C, and it was
not performed on RIE respiratory samples submitted for viral diagnosis.
Extraction of DNA. DNA was extracted from control organisms by
using the Wizard genomic DNA extraction kit (Promega, Southampton,
United Kingdom) following the manufacturer’s instructions. Extraction
of DNA from sputum and throat swab samples was performed by using a
Chelex-based extraction method; following centrifugation at 13,000  g
for 10 min, resulting pellets were washed three times with sterile phos-
phate-buffered saline (PBS), resuspended with PCR-grade water (5 the
pellet volume), and vortexed with 10% Chelex (Sigma, Poole, United
Kingdom) at a ratio of 1:1. After incubation at 56°C for 30min followed by
94°C for 5 min, the samples were vortexed, cooled on ice, and then cen-
trifuged at 13,000 g for 2min, and the resulting supernatants were used
for PCR.
TheDNA from respiratory samples for respiratory virus screeningwas
extracted using the easyMAG system (bioMérieux, United Kingdom) and
eluted into 100-l volumes. All extracts were stored at20°C until used.
M. amphoriforme 16S rRNA gene PCR. All oligonucleotides used in
this study are listed in Table 1. The DNA extracts from all patient groups
were tested for the presence ofM. amphoriforme via the 16S rRNA PCR as
previously described (2). The identity of the amplicons from at least the
first positive sample fromeach patientwas confirmed by sequencing using
standard Sanger sequencing protocols. The sequences were analyzed us-
ing BioNumerics software version 3.5 (Applied Maths) and aligned using
the CLUSTALWmultiple sequence alignment program (8). The consen-
sus sequences were compared to the 16S rRNA gene sequence from the
preliminary contiguous M. amphoriforme strain A39T whole-genome se-
quence obtained from the Wellcome Trust Sanger Institute.
M. amphoriforme qPCRs. The oligonucleotides for the M. amphori-
forme udg quantitative real-time PCR (Table 1) were designed and opti-
mized. The optimized M. amphoriforme qPCR protocol consisted of 5 l
of templateDNA, 1 Invitrogen PlatinumQPCR SuperMix-UDG, 7mM
MgCl2, 0.3 M primer MAudgF, 0.9 M primer MAudgR, and 0.25 M
probeMAudgP, in a final volume of 25 l. The reactions were performed
in a RotorGene 3000 apparatus (Qiagen, United Kingdom) under cycling
conditions of 95°C for 3 min followed by 35 cycles of 95°C for 15 s and
58°C for 60 s. Results were analyzed with the cycle threshold set at 0.03.
The standard curves were constructed in two independent experiments
on serial 10-fold dilutions ofM. amphoriformeDNA in triplicate samples.
The specificity of the assay was confirmed by the amplification of 1 ng of
DNA from the control organisms listed above, in duplicate. The identities
of amplicons were confirmed by Sanger sequencing.
The udg qPCRwas performed on the DNA extracts from patients with
PAD. Samples were tested neat, diluted 1:10, and spiked (4 l of sample
and 1 pg/lM. amphoriformeDNA, to detect sample inhibition). Samples
positive both neat and at a 10-foldDNAdilutionwere considered positive,
and samples that were only positive either neat or at a 10-fold dilution
were considered equivocal. To avoid bias due to sample storage, all sam-
ples with discrepant results were retested using the 16S rRNA PCR.
A quantitative real-time PCR assay targeting the variable region of the
23S rRNA gene unique forM. amphoriformewas designed and optimized.
TABLE 1 Oligonucleotides used in this study
Target Oligonucleotide (5=–3=)a
Product
size (bp)
udg MAudgF, TGCGGCCGATAAAACCGAAATAT 92
MAudgR, TTTCGAAAAGGGTTTGCTACCAA
Probe, FAM-TTGTGCTCATCCTTCACCC
TTTAGTGTGCA-BHQ1
23S rRNA Forward, GGGGTTCAAATAACAAGTC 106
Reverse, CGTGATATATGGCTCTTCG
16S rRNA Amph-f, AAGCTAGTAAAGGAAATGTTATT 594
Amph-r, ACTATAGAAATATAGTC
a FAM, 6-carboxyfluorescein; BHQ1, black hole quencher 1.
Ling et al.
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Aliquots of 2 l of template DNA were amplified in a 20-l reaction
mixture with 1 Sso Fast mix (Bio-Rad, United Kingdom) and 200 nM
each primer (Table 1). The PCRs were carried out in a RotorGene Q
thermocycler (Qiagen,UnitedKingdom) set to a thermal cycling program
of 95°C for 2 min, 40 cycles of 95°C for 15 s and 60°C for 1 min, with
fluorescence detection at an excitationwavelength of 470 nmand an emis-
sion wavelength of 510 nm, and a final melt curve analysis. The specificity
of the assay was tested in silico and in vitro by amplification of non-M.
amphoriforme DNA. The detection and quantification limits of the assay
were established onM. amphoriformeNCTC 11740DNA. To further con-
firm the specificity of the assays, the identities of the amplicons were
confirmed by sequencing.
The 23S rRNA PCR was used for M. amphoriforme identification in
RIE respiratory samples for viral screening. The DNA samples were
pooled in groups of 10. The DNA from individual samples from positive
pools underwent the same 23S rRNA PCR amplification to determine
individual results.
Nucleotide sequence accession numbers. The M. amphoriforme 16S
rRNA sequence from the single sample that was positive for M. amphori-
forme among patients attending the RFL Chest Clinic was deposited with
GenBank and assigned the accession number HM235449. Among the
patients with suspected LRTI, the M. amphoriforme rRNA sequences for
the four positive samples were submitted to GenBank and assigned acces-
sion numbers HM235442 to HM235446. The GenBank accession num-
bers for M. amphoriforme 16S rRNA sequences or the udg gene (n  14
and 1, respectively) from samples from the RFL Immunodeficiency Clinic
patient group are HM235425 to HM235439.
RESULTS
Analytical specificity and sensitivity of M. amphoriforme-spe-
cific qPCR assays. We designed two novel qPCR assays for the
identification of M. amphoriforme. Both assays were screened for
their specificity in silico and experimentally tested against the
DNA of 35 isolates, including Mycoplasma spp. and respiratory
pathogens. Both qPCR assays were positive only for M. amphori-
forme. PCR products were, however, obtained for A. laidlawi, M.
alvi, and M. genitalium with the 16S rRNA PCR. The limit of
quantificationwas 0.01 to 0.1 pg ofM. amphoriformeDNA, equiv-
alent to 9 to 90 organisms per reaction mixture for the udg PCR
and 20.6 (95% confidence interval, 2.8 to 149.2) copies per reac-
tion mixture for the 23S rRNA PCR, respectively.
M. amphoriforme in patients attending the RFL Immunode-
ficiencyClinic.M. amphoriforme culture, 16S rRNAPCR, andudg
qPCR were performed on 281 sputum samples from 88 patients
with PAD who attended the RFL Immunodeficiency Clinic. Of
these, culture was performed on 278 samples, 16S rRNA PCR was
done on 275 samples, and udg qPCR was performed on 263 sam-
ples. M. amphoriforme was detected by culture and/or PCR in the
sample from at least 1 of 17 (19.3%) patients. A positive culture
was obtained for 10 patients (37 samples out of 278; 13.3%), 16S
rRNA PCR was positive for 17 patients (70/275; 25.5%), and
qPCR was positive for 14 patients (64/263; 24.3%). These results
are summarized in Table 2.Multiple samples tested positive for 11
of the 13 patients for whommultiple samples were received, with
positivity lasting for 197 to 1,627 days. Estimated bacterial loads
were106 organisms per ml of sputum in at least one sample for
10 positive patients. Routine microbiology results were available
for 70 samples from 15M. amphoriforme-positive patients and for
39 samples from18matched negative patients. Known respiratory
pathogens, includingH. influenzae, S. pneumoniae,M. catarrhalis,
and P. aeruginosa, were found in moreM. amphoriforme-negative
sputum samples (59%) than inM. amphoriforme-positive samples
(24%). H. influenzae was the most commonly isolated pathogen
(18% of all samples) and was found significantly less often in M.
amphoriforme-positive samples (P 0.003, Fisher’s exact test).
M.amphoriforme in patients attending theRFLChestClinic.
A total of 38 sputum samples from 37 patients attending the RFL
Chest Clinic were tested. Of these patients, 17 had a diagnosis of
chronic obstructive pulmonary disease, 14 had bronchiectasis,
and 1 patient had both conditions. Culture results indicated nor-
mal respiratory tract flora in 15 samples, H. influenzae in 4 sam-
ples, 4 samples with S. aureus, and 15 samples with single isolates
of Acinetobacter, Pseudomonas, or Citrobacter sp. In this group,
there was a single sample positive for M. amphoriforme (Table 2):
a patient who had been taking clarithromycin for an exacerbation
of symptoms and in whom no other significant pathogen was
found.
M. amphoriforme in patients with suspected LRTI. M. am-
phoriforme was detected in 4 (5%) out of 80 patients with LRTI
(who had been recruited from general practices): 1/80 throat
swabs and 3/50 sputum samples were positive by 16S rRNA PCR
(Table 2). The identities of all PCR-positive amplicons were con-
firmed by sequencing, and the sequences were submitted to
GenBank. None of the control samples (49 throat swabs from
healthy individuals) were positive. All fourM. amphoriforme-pos-
itive samples were taken from patients with clinical signs of acute
LRTI, including raised pulse rate, respiratory rate, and C-reactive
protein concentration compared with the controls. None had a
history of recent travel, alcohol consumption, or steroid treat-
ment. Other respiratory organisms were detected in two of theM.
amphoriforme-positive patients; coronavirus, human rhinovirus,
H. influenzaeplus Streptococcus pneumoniae in the patientwith the
M. amphiforme-positive throat swab, and enterovirus in a patient
with M. amphiforme-positive sputum.
M. amphoriforme in patients with suspected respiratory vi-
ral infection. The respiratory samples screened for suspected
LRTI used in this study were collected between 1March 2011 and
11 March 2012. Out of 10,747 (3,496 from adults and 7,251 from
children) respiratory samples from 7,139 patients (2,524 adults
and 4,615 children), 23 samples from 19 patients (6 adults and 13
children) tested positive in theM. amphoriforme 23S rRNA qPCR
TABLE 2 Comparison of M. amphoriforme detection rates for different patient groups tested by culture, 16S rRNA PCR, and qPCR
Patient group
% positive samples (no. positive/total no. of samples)
Culture 16S rRNA PCR qPCR Total
Immunodeficiency Clinic patients 11.36 (10/88) 19.32 (17/88) 16.09 (14/87) 19.32 (17/88)
Chest Clinic patients NTa 2.70 (1/37) NT 2.70 (1/37)
Patients with LRTI NT 3.08 (4/80) NT 3.08 (4/80)
Patients with suspected viral LRTI NT NT 0.27 (19/7,139) 0.27 (19/7,139)
a NT, not tested.
Mycoplasma amphoriforme Detection
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(Table 2). The positive sample sources included nasopharyngeal
secretions (6), nose throat swab (1), throat swabs (8), throat swabs
for virology (3), sputum (1), and induced sputum (1), and they
originated from the Accident and Emergency Unit (12), Intensive
Treatment Unit/HighDependency Unit (4), Children’sWard (4),
Infectious Diseases (1), Hematology (1), and Neonatal Unit (1).
No other respiratory pathogen was found in 13 samples, and 10
samples had viral coinfection, as detected by real-time PCR, with
the following viruses: rhinovirus (4), RSV (3), adenovirus and
influenza B viruses (1), human metapneumovirus (hMPV) (1)
and parainfluenza virus 2 (1).
DISCUSSION
To better understand the epidemiology and pathogenesis of M.
amphoriforme infection, it is necessary to develop new sensitive
and quantitative tools for diagnosis. Due to the fastidious growth
of humanmycoplasmas, sensitive molecular tools are an essential
prerequisite for their identification in order to diagnose infection
in a timely manner, so that antimicrobial treatment can be initi-
ated. In this paper, we have described two real-time PCR assays,
defined their specificity, and described our evaluation of them in a
clinical practice environment.
Specificity of theqPCRassays.TheqPCRassaysweused target
the udg gene and the M. amphoriforme-specific region of the 23S
rRNAgene. Both qPCRswere specific forM. amphoriforme as they
were negative for all other tested species. In contrast, the 16S
rRNA PCR was positive for three mycoplasma-related species: A.
laidlawii, M. genitalium, and M. alvi. A. laidlawii can be found in
the human oropharynx, and althoughM. genitalium is primarily a
genitourinary tract pathogen of humans, there have been reports
of its detection in respiratory samples (9); theymay therefore rep-
resent a possibility for false-positive results. M. alvi has only been
found in cattle, and there is no evidence of its presence in humans
(10). The high specificity of the real-time assays was further con-
firmed by sequencing of products, which showed that all positive
samples contained M. amphoriforme-specific sequences.
The assays were able to detect an estimated single to several
copies per reaction mixture and can be used to measure the bac-
terial load. The high sensitivities of the qPCRs may be important
in defining the pathogenic potential ofM. amphoriforme in future
studies, as has been the case for other organisms, such asM. geni-
talium (11, 12). Moreover, a sensitive detection method will im-
prove detection if suboptimal samples are used, as it is not yet clear
what is the primary niche ofM. amphoriforme in the human host.
M. amphoriforme in samples frompatients with immunode-
ficiency. The 16S rRNA PCR and qPCR provided more sensitive
detection than culture, identifyingM. amphoriforme in 17 patients
(25.5% positive samples) and 14 patients (24.3% positive sam-
ples), respectively, versus 10 culture-positive patients (13.3% pos-
itive samples). The qPCR gave an equivocal signal for one sample
and was negative for another sample for two patients for whom
only a single sample was available for the analysis. However, these
samples were positive by the 16S rRNA PCR but negative by cul-
ture. These results may have arisen through undetected inhibition
or loss of DNA during extraction. There was a single sample from
one patient positive by the 16S rRNA PCR that was not available
for the qPCR and that was negative by culture. The high incidence
of M. amphoriforme (19.3%) in sputa of PAD patients suggests
that it may be an important cause of infection in this patient
group. Although it is difficult to assign the clinical significance of
M. amphoriforme in this complex group of patients, our data show
that M. amphoriforme can chronically infect PAD patients and
may contribute to LRTI and the pathogenesis of lung disease. Fur-
ther research should be conducted to characterize M. amphori-
forme pathogenicity in this patient group.
M. amphoriforme from samples from the Chest Clinic and
frompatientswith LRTI.A single sample from among those of 37
patients attending the Chest Clinic was positive for M. amphori-
forme. These patients are known to be susceptible to a wide range
of pathogens that cause chronic sepsis, and further studies in
larger groups of patients are required. The detection rate of M.
amphoriforme (5%) in patients with acute signs of LRTI who were
recruited from general practices was similar to that of other
known respiratory pathogens, including Haemophilus influenzae
(6%), coronaviruses (6%), and parainfluenza viruses (4%) (5).
Coinfections were a common feature of this patient group (22.5%
of patients and 4% of controls), and therefore, the coinfection of
the M. amphoriforme-positive sample with other organisms does
not exclude its etiological role in the LRTI. It was notable that M.
amphoriforme was not detected in control subjects, as these sam-
ples were exclusively throat swabs. It opens the possibilities that
this observation was due to the sample type or that M. amphori-
forme is a primary respiratory pathogen. However, one throat
swab from a patient was M. amphoriforme positive in this study,
and throat swabs are recommended for the detection of other
Mycoplasma spp. (13). In addition, other respiratory pathogens,
such as S. pneumoniae and viral pathogens, were detected when
throat swabs were employed at their expected frequency (5).
M. amphoriforme in samples from patients with suspected
respiratory viral infection. The largest group in this study was a
1-year collection of 10,747 respiratory samples submitted for
virological testing from patients with suspected respiratory infec-
tion. InfectionwithM. amphoriformewas found to be uncommon
within this group, with an incidence of 0.21%.
The low incidence we found was not likely caused by sample
pooling, as this approach has previously proved successful in the
detection of hMPV in clinical samples (14). The study described
here is a pilot study with sampling protocols and DNA extraction
methods that are not yet optimized for this organism. Thus, the
low detection rate may have been because this is not an optimal
sampling method. Additionally, other Mycoplasma species have
periodicity in their detection rates, for example, M. pneumoniae
infection increases in prevalence every 4 to 7 years (15, 16) The
longest study period reported here was 1 year; thus, longitudinal
studies are now required to elucidate the periodicity of M.
amphoriforme infection. In this study, positive results weremostly
found in children (68% of the positive patients), but this may
reflect the distribution of the samples submitted for testing. An
age cross-sectional study is now required. Viral coinfection was
present in 10 M. amphoriforme-positive samples, all from chil-
dren. Interestingly, viral infection was not detected in any of the
M. amphoriforme-positive samples from adult patients. The re-
sults from this preliminary study will provide the basis for a larger
study of a wide range of samples from patients presenting with
symptoms and signs of LRTI.
The results reported here are important pilot data for the study
of M. amphoriforme and the first step in understanding its wider
pathogenicity. Taken together, these data provide support for M.
amphoriforme as a primary respiratory pathogen. However, these
studies should be repeated by other groups in different countries,
Ling et al.
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andwe are currently workingwith partners to perform suchwork.
The importance of this paper is that it provides a methodology
that will assist other groups in diagnosingM. amphoriforme infec-
tion, and it is only by increasing the number of patients identified
with this organism that we will be able to determine its pathogenic
potential with certainty.
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